Fig. 4: Predictive impacts of genomic alterations in metastatic castration-sensitive prostate cancer (mCSPC). | BJC Reports

Fig. 4: Predictive impacts of genomic alterations in metastatic castration-sensitive prostate cancer (mCSPC).

From: Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project

Fig. 4

Time to castration-resistant prostate cancer (CRPC) according to presence or absence of homologous recombination repair (HRR) defect in mCSPC patients treated with androgen deprivation therapy (ADT)/combined androgen blockade (CAB) (left) or ADT plus androgen receptor pathway inhibitor (ARPI) (right).

Back to article page